Earnings summaries and quarterly performance for THERMO FISHER SCIENTIFIC.
Executive leadership at THERMO FISHER SCIENTIFIC.
Marc N. Casper
Detailed
Chief Executive Officer
CEO
FL
Frederick Lowery
Detailed
Executive Vice President
GP
Gianluca Pettiti
Detailed
Executive Vice President
JR
James R. Meyer
Detailed
Senior Vice President and Chief Financial Officer
ML
Michel Lagarde
Detailed
Executive Vice President and Chief Operating Officer
SW
Stephen Williamson
Detailed
Senior Vice President and Chief Financial Officer
Board of directors at THERMO FISHER SCIENTIFIC.
CM
C. Martin Harris
Detailed
Director
DL
Debora L. Spar
Detailed
Director
DJ
Dion J. Weisler
Detailed
Director
JC
James C. Mullen
Detailed
Director
JM
Jennifer M. Johnson
Detailed
Director
KS
Karen S. Lynch
Detailed
Director
NJ
Nelson J. Chai
Detailed
Director
RA
R. Alexandra Keith
Detailed
Director
RR
Ruby R. Chandy
Detailed
Director
SM
Scott M. Sperling
Detailed
Lead Independent Director
TJ
Tyler Jacks
Detailed
Director
Research analysts who have asked questions during THERMO FISHER SCIENTIFIC earnings calls.
Jack Meehan
Nephron Research LLC
6 questions for TMO
Also covers: A, AVTR, BIO +17 more
Tycho Peterson
Jefferies
6 questions for TMO
Also covers: A, AVTR, BIO +22 more
Michael Ryskin
Bank of America Merrill Lynch
5 questions for TMO
Also covers: A, ALGN, AVTR +28 more
Daniel Brennan
TD Cowen
3 questions for TMO
Also covers: A, ADPT, AVTR +24 more
Douglas Schenkel
Wolfe Research, LLC
3 questions for TMO
Also covers: A, AVTR, BRKR +21 more
RV
Rachel Vatnsdal Olson
JPMorgan
3 questions for TMO
Also covers: A, ADPT, AKYA +14 more
Andrew Cooper
Raymond James
2 questions for TMO
Also covers: AZTA, CDNA, CTKB +12 more
Dan Arias
Stifel Financial Corp.
2 questions for TMO
Also covers: A, GH, ILMN +9 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for TMO
Also covers: A, ADPT, AVTR +21 more
Patrick Donnelly
Citi
2 questions for TMO
Also covers: A, AVTR, BIO +21 more
DB
Dan Brennan
UBS
1 question for TMO
Also covers: A, DHR, MDXH +7 more
Daniel Anthony Arias
Stifel
1 question for TMO
Michael Leonidovich Ryskin
Bank of America
1 question for TMO
PS
Puneet Souda
Leerink Partners
1 question for TMO
Also covers: A, ABCL, BRKR +20 more
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for TMO
Also covers: A, AKYA, AVTR +11 more
Recent press releases and 8-K filings for TMO.
Thermo Fisher details 2025 performance and 2026 outlook
TMO
Guidance Update
M&A
Share Buyback
- Thermo Fisher delivered $44 billion in revenue in 2025, supported by >120,000 colleagues and $1.4 billion in R&D investment.
- Operational excellence driven by the PPI Business System, including $300 million of cost actions and tariff adjustments to bolster resilience.
- Executed strategic capital deployment: closed the $4 billion Solventum Purification & Filtration acquisition and Sanofi Steriles site, announced the $9 billion Clario deal, and returned capital with $3 billion in share repurchases and $600 million in dividends.
- Outlook for 2026 includes improving demand trends with organic revenue growth progression and strong adjusted EPS growth.
1 day ago
Thermo Fisher reviews 2025 performance and sets 2026 outlook
TMO
Guidance Update
M&A
- Delivered $44 billion in revenue, employs 120,000 staff and invests $1 billion annually in R&D in 2025.
- Achieved mid-single-digit organic growth in pharma & biotech (first nine months of 2025) and surpassed an incremental $300 million cost-reduction target.
- Deployed capital through the acquisition of Solventum’s purification & filtration business (approx. $750 million revenue run rate) and a Sanofi fill-finish site, and announced the $9 billion Clario acquisition.
- Forecasts 3 %–6 % organic top-line growth for 2026, with a long-term target of returning to 7 %+ growth and 50–70 bps of annual margin expansion.
- Serves four end markets—56 % of 2025 revenue from pharma & biotech—within a $270 billion addressable market and holds ~20 % market share.
1 day ago
Thermo Fisher outlines 2025 results and 2026 outlook at JP Morgan Healthcare Conference
TMO
Guidance Update
M&A
- In 2025, Thermo Fisher achieved $44 billion in revenue, launched key products (Orbitrap Astral mass spectrometer, next-generation cryo-EM, scalable single-use bioreactors) and returned $3.6 billion to shareholders via buybacks and dividends
- Expanded portfolio through acquisitions: Solventum filtration platform (
$750 million revenue run-rate), Sanofi’s Ridgefield sterile fill-finish site and announced Clario deal ($1.25 billion revenue; $0.45 EPS accretion in year one) - Financial outlook targets 3%–6% organic revenue growth in 2026–27 with 50–70 bp annual margin expansion, transitioning to >7% organic growth post-2028; strategic execution powered by the PPI system and AI partnerships (OpenAI, NVIDIA)
- Advanced corporate social responsibility: >56% of global electricity from renewables (target 80% by 2030), 33 zero-waste sites and ongoing investments in education and health equity initiatives
1 day ago
Thermo Fisher outlines 2025 performance and 2026 strategy at JPMorgan Healthcare Conference
TMO
Product Launch
M&A
Share Buyback
- Thermo Fisher reported $44 billion in 2025 revenue and has delivered an average 10 % annual top-line growth over the past decade.
- The company launched key innovations in mass spectrometry (Orbitrap Astral), cryo-electron microscopy, scalable bioreactors, and diagnostics to support market share gains.
- Thermo Fisher completed the Solventum filtration acquisition and Sanofi Ridgefield site purchase, announced the $9 billion Clario deal, and returned $3.6 billion via share repurchases and dividends in 2025.
- For 2026, management will prioritize trusted partnerships, further product innovation, operational excellence through PPI and AI, active capital deployment, and advancing CSR initiatives.
1 day ago
Thermo Fisher Scientific announces AI collaboration with NVIDIA
TMO
New Projects/Investments
- Thermo Fisher partners with NVIDIA to integrate AI infrastructure—including NVIDIA DGX Spark™, NeMo™, and BioNeMo™—into its scientific instruments and lab software, aiming to automate workflows and enhance lab performance.
- The collaboration seeks to reduce manual steps in experiment design, sample preparation, and data interpretation, accelerating scientific discoveries through smarter, connected lab workflows.
- Thermo Fisher’s ecosystem, spanning instruments, consumables, software, and services, will leverage NVIDIA’s AI platform to further amplify laboratory productivity.
- With annual revenue exceeding $40 billion, Thermo Fisher strengthens its leadership in life sciences by embedding AI into its offerings to make laboratories healthier, cleaner, and safer.
2 days ago
Thermo Fisher Scientific Tenant Underpins OlivePoint’s Raleigh Office Acquisition
TMO
New Projects/Investments
M&A
- OlivePoint Capital, partnering with Redwood Capital, acquired the 220,000-square-foot Class A office building at 3900 Paramount Parkway in RTP, Raleigh–Durham.
- The property is 100% leased to PPD, a subsidiary of Thermo Fisher Scientific, providing long-duration, credit-backed cash flows with full corporate support.
- The acquisition was made at a meaningful discount to replacement cost and an attractive in-place yield, reflecting OlivePoint’s strategy to capitalize on office sector dislocation.
- Located adjacent to a campus of 375+ biotech, pharma, tech, and manufacturing firms, Raleigh–Durham ranks among the top U.S. markets for long-term population and income growth, underpinning asset value.
- This transaction enhances OlivePoint’s Office Special Situations Strategy, targeting high-quality, credit-backed assets in stressed markets to exploit mispriced opportunities.
Dec 15, 2025, 3:11 PM
Thermo Fisher Scientific issues €2.1 billion senior notes
TMO
Debt Issuance
- Thermo Fisher Scientific (Finance I) B.V. issued €1.0 billion Floating Rate Senior Notes due December 1, 2027 (3-month EURIBOR + 0.28%) and €1.1 billion 3.628% Senior Notes due December 1, 2035, fully and unconditionally guaranteed by Thermo Fisher Scientific Inc.
- The 2027 notes were priced at 100% of par with quarterly interest, and the 2035 notes at 100% of par yielding 3.628% (spread of +88 bps to mid-swaps; make-whole +15 bps; par call from September 1, 2035)
- Net proceeds are expected to be approximately €2.09 billion after underwriting discounts and expenses, to be used for general corporate purposes including acquisitions, debt refinancing, working capital and equity repurchases
- Notes are expected to settle on December 1, 2025, managed by lead managers Barclays, BNP Paribas, HSBC Continental Europe and Morgan Stanley, with a planned listing on the New York Stock Exchange
Dec 1, 2025, 9:15 PM
Thermo Fisher Scientific authorizes $5B share repurchase
TMO
Share Buyback
- Thermo Fisher’s Board approved a $5 billion share repurchase program to be executed in the open market or via negotiated transactions.
- The authorization has no expiration date, granting management flexibility on timing and pricing.
- Thermo Fisher generated approximately $40 billion in annual revenue, underscoring its market leadership.
Nov 6, 2025, 9:35 PM
Vaxcyte reports Q3 2025 financial results and VAX-24 Phase 2 study update
TMO
Earnings
New Projects/Investments
Hiring
- Ended Q3 with $2,670.6 million in cash, cash equivalents and investments, expected to fund operations into mid-2028.
- Shared final VAX-24 infant Phase 2 data showing robust, dose-dependent immune responses and minimal carrier suppression, validating higher doses for the ongoing VAX-31 infant study.
- Entered a $1 billion agreement with Thermo Fisher for fill-finish capacity in North Carolina to bolster U.S. commercial supply.
- Appointed Mike Mullette as Chief Commercial Officer to lead PCV program commercialization.
- Q3 R&D expenses were $209.9 million (vs. $116.9 million Y/Y), G&A expenses $32.4 million (vs. $23.0 million Y/Y), and net loss $212.8 million (vs. $103.1 million Y/Y).
Nov 4, 2025, 9:05 PM
Thermo Fisher plans $9B acquisition of Clario
TMO
M&A
Debt Issuance
- Thermo Fisher agreed to acquire Clario Holdings for approximately $8.9 billion in cash plus up to $525 million in performance-linked payments, marking one of the year’s largest private equity exits.
- Clario’s platform, which generates around $1.25 billion in revenue, supports data collection and analysis for clinical trials and underpins 70% of U.S. drug approvals.
- The deal is expected to close by mid-2026 pending regulatory approval and will bolster Thermo Fisher’s software and AI capabilities within its Laboratory Products and Biopharma Services segment.
- Thermo Fisher will fund the transaction with debt financing and cash on hand, and WilmerHale advised on the deal with a 40-lawyer multidisciplinary team.
- The acquisition is projected to be immediately accretive, adding $0.45 of adjusted EPS in the first year after closing.
Oct 29, 2025, 4:49 AM
Quarterly earnings call transcripts for THERMO FISHER SCIENTIFIC.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more